CC16 Expression Restoration in Sputum of People With Cystic Fibrosis After Initiation of Elexacaftor/Tezacaftor/Ivacaftor

Mottais, Angélique;Detry, Bruno;Qiu, Ziyu;Collin, Amandine;Gohy, Sophie;et.al.
(2026) Archivos de Bronconeumologia — Vol. 62, n° 2, p. 121-125 (2026)

Files

Mottaisetal2025CC16.pdf
  • Open Access
  • Adobe PDF
  • 1.66 MB
Download

Details

Authors
Show more
Abstract
(en) Cystic fibrosis (CF) is a rare genetic autosomal recessive disease caused by mutations in the CF transmembrane con- ductance regulator (CFTR) gene. This muco-obstructive lung disease is accompanied by repeated cycles of inflammation with excessive neutrophil infiltrates and infections (e.g. Pseu- domonas aeruginosa (Pa)), leading to remodelling of the respiratory epithelium. Highly effective modulator therapies, e.g. elexa- caftor/tezacaftor/ivacaftor (ETI), have considerably changed the life expectancy of people with CF (pwCF) in medicalised countries with an impressive improvement in CF clinical outcomes. [...]
Affiliations

Citations

  • APA
  • Chicago
  • FWB

Mottais, A., Detry, B., Qiu, Z., Collin, A., Lecocq, M., Bouzin, C., Chamlou, C., Bruart, C., de Fays, C., vanaudenaerde Bart, Dupont Lieven, Vermaut astrid, Schulte Mariane, Boon Mieke, Goubau, C., Berardis, S., Hox, V., Froidure Antoine, Pilette, C., & Gohy, S. (2026). CC16 Expression Restoration in Sputum of People With Cystic Fibrosis After Initiation of Elexacaftor/Tezacaftor/Ivacaftor. Archivos de Bronconeumologia, 62(2), 121-125. https://doi.org/10.1016/j.arbres.2025.07.022 (Original work published 2026)